Accueil
Explorer
nav.journalClub
Tendances
Plus
synapse
⌘+K
Langue
Français
Français
March 3, 2026
Pharmacotherapy for obesity management—Emphasizing the role of GLP-1 receptor agonist-based therapeutics
BW
Bruce A. Warden
Oregon Health & Science University
PD
Paul Barton Duell
JB
John D. Bucheit
Virginia Commonwealth University
See all
Key Points
GLP-1 receptor agonists significantly enhance weight management and appetite control in patients with obesity.
A meta-analysis of multiple trials reveals a reduction of up to 10% in body weight with GLP-1 therapies.
Observational analysis focused on pharmacotherapy interventions in managing obesity-related metabolic pathways.
These findings support the potential of GLP-1 receptor agonists as a key therapeutic strategy for obesity treatment.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Pharmacotherapy for obesity management—Emphasizing the role of GLP-1 receptor agonist-based therapeutics | Synapse
Cite This Study
Copy
Warden et al. (Thu,) studied this question.
synapsesocial.com/papers/69a759e3c6e9836116a1f46a
https://doi.org/https://doi.org/10.1016/j.jacl.2025.11.013